Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 12

1871P - Temperature-controlled hand-foot cooling combined with compression prevents chemotherapy-induced polyneuropathy (CIPN): A single center, prospective, real-world data collection

Date

14 Sep 2024

Session

Poster session 12

Topics

Supportive Care and Symptom Management;  Cytotoxic Therapy;  Management of Systemic Therapy Toxicities

Tumour Site

Breast Cancer

Presenters

Athina Kostara

Citation

Annals of Oncology (2024) 35 (suppl_2): S1077-S1114. 10.1016/annonc/annonc1612

Authors

A. Kostara, J. Rodemann, M. Harms, O. Opra

Author affiliations

  • Gynecological Oncology, MVZ Medical Center Duesseldorf, 40235 - Duesseldorf/DE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1871P

Background

Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect of taxane (Paclitaxel, nab-Paclitaxel, Docetaxel). CIPN could reduce long-term quality of life (Blackley et al, 2019) and result in dose delays, reductions or treatment discontinuations. Temperature-controlled hand-foot cooling (Hilotherapy®) prevents CIPN (Oneda et al. 2020&2021, Coolbrandt et al. 2022). Prospectively collected data of 151 breast cancer patients showed that cooling using 1st generation cuffs with 30 minutes post-cooling prevents CIPN ≥ 2° in 93,4% of patients undergoing taxane-based chemotherapy (Schaper et al. in prep.). The development of 2nd generation, combined cooling-compression cuffs, ensures even more effective skin cooling. This raises the question, whether cooling time could be safely reduced.

Methods

We used prophylactic cooling with 2nd generation cuffs as standard of care during chemotherapy without the recommended 30 minutes post-cooling, due to capacity issues, and investigated the efficacy of the 2nd generation cuffs regarding prevention of CIPN through surveys. Patients were stratified according to dosing schedule (q1w vs q3w). Follow-up data will be collected to report the sustainability of the results.

Results

181 breast cancer patients completed their taxane-based chemotherapy using 2nd generation cuffs without post-cooling. 169 (93,4%) patients showed symptoms of CIPN 0-1° and 12 (6,6%) of CIPN 2°. No patient reported grade 3 toxicity. Data collection is still in process and follow-up will be updated to examine the sustainability of the results.

Conclusions

Prophylactic temperature-controlled hand-foot cooling combined with compression (Hilotherapy® 2nd generation) without the recommended 30 minutes post-cooling effectively prevents the development of severe CIPN ≥ 2°.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

ISI e.V. - International Senology Initiativ.

Disclosure

A. Kostara: Non-Financial Interests, Personal and Institutional, Advisory Board, Study Equipment funding: Hilotherm GmbH. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.

  • Analytics cookies help us improve our website by collecting and reporting information on its usage.

  • We use marketing cookies to build a profile of you as a user through your actions on our site in order to better understand your interests and provide you with pertinent suggestions.